The Journey of Vancomycin

Vancomycin is not absorbed from the intact gastrointestinal tract
— oral bioavailability is effectively 0% in healthy individuals because of its large molecular
size (~1,449 Da) and amphiphilic glycopeptide structure. This non-absorption is a pharmacological
feature exploited therapeutically: oral vancomycin (125-500 mg four times daily) acts locally
in the gut lumen to treat Clostridioides difficile colitis without systemic exposure. For
all systemic infections (MRSA bacteremia, endocarditis, meningitis, pneumonia, bone and joint
infections), vancomycin must be administered intravenously. The drug must be infused slowly
(over at least 60 minutes, preferably 90-120 minutes for doses >1 g) to prevent "Red Man Syndrome"
— a non-IgE-mediated histamine release reaction causing flushing, erythema, and hypotension of
the upper body from rapid infusion. Intramuscular injection causes intense pain and is not used.

Vancomycin distributes into extracellular fluid compartments
with a volume of distribution of approximately 0.4-1.0 L/kg (conventional) to 0.7-1.5 L/kg (in
critically ill patients with altered fluid distribution). Plasma protein binding is approximately
55%, primarily to albumin. The drug distributes well into pleural fluid, ascites, and synovial fluid.
Penetration into the CNS is limited with intact meninges (approximately 10-15% of plasma) but
increases with meningeal inflammation to 20-30% — sufficient for gram-positive meningitis treatment
(bacterial meningitis due to MRSA, Listeria, or pneumococcus resistant to penicillin). Lung tissue
penetration is relatively poor (epithelial lining fluid concentrations approximately 30-40% of plasma),
which contributes to the relatively high MIC breakpoints needed for pneumonia vs. bacteremia.
Bone concentrations reach approximately 6-13% of serum levels, requiring high AUC targets for
osteomyelitis.

Vancomycin inhibits cell wall synthesis by a mechanism fundamentally
distinct from beta-lactam antibiotics. Rather than binding enzymes, vancomycin binds directly to
the substrate — the D-Ala-D-Ala terminus of lipid II (undecaprenyl pyrophosphate-MurNAc-pentapeptide),
the key peptidoglycan precursor anchored in the outer leaflet of the cytoplasmic membrane awaiting
incorporation into the growing cell wall. Vancomycin's five-ring scaffold forms five hydrogen bonds
with the D-Ala-D-Ala dipeptide terminus through a complementary binding "pocket." This binding
physically blocks transglycosylase enzymes from transferring the disaccharide-peptide unit onto
the growing glycan strand, and blocks transpeptidases from crosslinking adjacent peptide chains.
The dual-target blockade (transglycosylation and transpeptidation) makes vancomycin bactericidal
against gram-positive organisms. Gram-negative bacteria are intrinsically resistant because the
outer membrane prevents access of vancomycin to the periplasm where lipid II resides.

Vancomycin is not significantly metabolized in humans — it is
excreted essentially unchanged. Unlike most antibiotics, no cytochrome P450 enzymes are involved in
vancomycin elimination; there are no known pharmacologically active or inactive metabolites formed
in vivo. Minor structural modifications may occur in urine (hydrolysis products) but are
pharmacologically negligible. The absence of hepatic metabolism means vancomycin pharmacokinetics
are primarily driven by renal function rather than liver function. However, vancomycin has a narrow
therapeutic window requiring therapeutic drug monitoring (TDM) — current guidelines recommend
monitoring via AUC/MIC ratio (target 400-600 mg·h/L for MIC ≤1 µg/mL) rather than traditional
trough monitoring, based on data showing AUC/MIC better predicts both clinical outcome and
nephrotoxicity risk than trough alone.

Vancomycin is eliminated almost entirely by renal excretion as
unchanged drug — approximately 90% is recovered in urine within 24 hours in patients with normal
renal function. Glomerular filtration is the primary elimination pathway; tubular secretion contributes
to a minor degree. Elimination half-life in patients with normal renal function is approximately
4-8 hours. In severe renal impairment (CrCl <10 mL/min), the half-life extends to 200-250 hours,
requiring dramatic dose interval extension. In patients receiving hemodialysis, vancomycin clearance
depends on the dialyzer membrane type: conventional dialyzers remove minimal vancomycin (weekly
dosing sufficient), while high-flux dialyzers remove approximately 40% per session (more frequent
monitoring required). Population pharmacokinetic dosing algorithms — incorporating weight, renal
function, and target AUC — are replacing older empirical weight-based regimens.

Vancomycin is the cornerstone therapy for MRSA infections (bacteremia,
endocarditis, pneumonia, osteomyelitis, meningitis) and for serious infections with other gram-
positive organisms resistant to beta-lactams. Nephrotoxicity is the major adverse effect — incidence
3-17% with monotherapy, higher with aminoglycoside co-administration. AUC/MIC-guided TDM reduces
nephrotoxicity without compromising efficacy. Ototoxicity (cochlear, vestibular) can occur with
very high concentrations, particularly with concurrent aminoglycosides. Resistance mechanisms include
vancomycin-resistant enterococci (VRE) carrying vanA/vanB genes, which reprogramme the ligases to
produce D-Ala-D-Lac instead of D-Ala-D-Ala (the altered terminus binds vancomycin with 1,000-fold
lower affinity). VISA (vancomycin-intermediate Staphylococcus aureus) achieves resistance by
cell wall thickening that traps vancomycin away from lipid II.